Valion Bio issues 1,287 Series A preferred shares in unregistered sale tied to $750,000 milestone payment

Valion Bio issued 1,287 shares of Series A Preferred Stock in an unregistered sale to Statera Biopharma and Avenue Venture Opportunities Fund.

The issuance is dated July 31, 2026. The securities were issued as consideration for a $750,000 milestone payment tied to inventory validation for distribution and sales.

The shares were sold in a private placement exemption under Section 4(a)(2) and/or Regulation D. The securities are restricted under Rule 144.

The company committed to file a resale registration statement within 60 days for the common stock underlying the Series A Preferred Stock.

Conversion is capped. Holders cannot exceed a beneficial ownership limit set between 4.9% and 19.9%.